Sugi Predict

Sugi Predict / Compounds / SCHEMBL19687918

SCHEMBL19687918

SCHEMBL19687918

CCOc1cc(C(=O)N[C@H](Cc2ccc(-c3cccc(Cl)c3)cc2)CC(C)(CO)C(=O)O)n[nH]1

nearest known ligand 0.59

Predicted protein targets (top 3)

geneUniProtsupporting neighboursconfidence
▸ MME P08473 17/20 0.59
▸ ACE P12821 3/20 0.51
▸ MMEL1 Q495T6 3/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20474779 1.00 MME (0.59) MMEACEMMEL1
SCHEMBL15474321 1.00 MME (0.59) MMEACEMMEL1
SCHEMBL22414055 0.94 MME (0.53) MMEACEMMEL1
SCHEMBL26381935 0.94 MME (0.53) MMEACEMMEL1
SCHEMBL15467835 0.88 MME (0.55) MMEACE
SCHEMBL19788065 0.88 MME (0.55) MMEACE
SCHEMBL9930452 0.85 MME (0.65) MMEACE
SCHEMBL15467397 0.83 MME (0.63) MMEACEMMEL1
SCHEMBL19687925 0.83 MME (0.63) MMEACEMMEL1
SCHEMBL26381954 0.82 MME (0.54) MMEMMEL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11634413-B2 Neprilysin inhibitors THERAVANCE BIOPHARMA R&D IP, LLC (US) 2023-04-25 — — US disclosed
US-20220106300-A1 NEPRILYSIN INHIBITORS THERAVANCE BIOPHARMA R&D IP, LLC (US) 2022-04-07 — — US disclosed
US-10570120-B2 Neprilysin inhibitors THERAVANCE BIOPHARMA R&D IP, LLC (US) 2020-02-25 — — US disclosed
US-20190276442-A1 NEPRILYSIN INHIBITORS THERAVANCE BIOPHARMA R&D IP, LLC (US) 2019-09-12 — — US disclosed
US-10189823-B2 Neprilysin inhibitors THERAVANCE BIOPHARMA R&D IP, LLC (US) 2019-01-29 — — US disclosed
US-10189823-B2 Neprilysin inhibitors THERAVANCE BIOPHARMA R&D IP, LLC (US) 2019-01-29 — — US disclosed
US-20180237423-A1 NEPRILYSIN INHIBITORS THERAVANCE BIOPHARMA R&D IP, LLC (US) 2018-08-23 — — US disclosed
US-9873685-B2 Neprilysin inhibitors THERAVANCE BIOPHARMA R&D IP, LLC (US) 2018-01-23 — — US disclosed
US-20170349574-A1 NEPRILYSIN INHIBITORS THERAVANCE BIOPHARMA R&D IP, LLC (US) 2017-12-07 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180237423-A1 NEPRILYSIN INHIBITORS MME, REN, ACE MME 1/4885ACE 3/4885MMEL1 240/4885
US-20220106300-A1 NEPRILYSIN INHIBITORS MME, REN, ACE MME 1/4885ACE 3/4885MMEL1 240/4885
US-11634413-B2 Neprilysin inhibitors MME, REN, ACE MME 1/4885ACE 3/4885MMEL1 240/4885
US-20170349574-A1 NEPRILYSIN INHIBITORS MME, REN, ACE MME 1/4885ACE 3/4885MMEL1 240/4885
US-10189823-B2 Neprilysin inhibitors MME, REN, ACE MME 1/4885ACE 3/4885MMEL1 240/4885
US-20190276442-A1 NEPRILYSIN INHIBITORS MME, REN, ACE MME 1/4885ACE 3/4885MMEL1 240/4885
US-10570120-B2 Neprilysin inhibitors MME, REN, ACE MME 1/4885ACE 3/4885MMEL1 240/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.